Li Jianzhuang, Wei Yanhao, Zhang Chunlin, Bi Rentang, Qiu Yanmei, Li Yanan, Hu Bo
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Pharmaceutics. 2023 Feb 13;15(2):621. doi: 10.3390/pharmaceutics15020621.
Neurological diseases (NDs) are a significant cause of disability and death in the global population. However, effective treatments still need to be improved for most NDs. In recent years, cell-membrane-coated nanoparticles (CMCNPs) as drug-targeting delivery systems have become a research hotspot. Such a membrane-derived, nano drug-delivery system not only contributes to avoiding immune clearance but also endows nanoparticles (NPs) with various cellular and functional mimicries. This review article first provides an overview of the function and mechanism of single/hybrid cell-membrane-derived NPs. Then, we highlight the application and safety of CMCNPs in NDs. Finally, we discuss the challenges and opportunities in the field.
神经疾病(NDs)是全球人口致残和死亡的重要原因。然而,大多数神经疾病的有效治疗方法仍有待改进。近年来,细胞膜包被纳米颗粒(CMCNPs)作为药物靶向递送系统已成为研究热点。这种源自膜的纳米药物递送系统不仅有助于避免免疫清除,还赋予纳米颗粒(NPs)各种细胞和功能模拟特性。本文首先概述了单一/混合细胞膜衍生纳米颗粒的功能和机制。然后,我们重点介绍了CMCNPs在神经疾病中的应用和安全性。最后,我们讨论了该领域的挑战和机遇。